Evidence map›Paper›PMID 28880936›Full record

ArticlePloS one2017

Reduced microRNA-503 expression augments lung fibroblast VEGF production in chronic obstructive pulmonary disease.

Jun Ikari, Amy J Nelson, Jannah Obaid, Alvaro Giron-Martinez, Kumiko Ikari, Fumihiko Makino, Shunichiro Iwasawa, Yoko Gunji, Maha Farid, Xingqi Wang and 7 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. International journal of chronic obstructive pulmonary disease · 2020
    Article
  7. Review
  8. Article
  9. Chemokines in COPD: From Implication to Therapeutic Use.International journal of molecular sciences · 2019
    Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 3 countries.

Jun IkariPulmonary, Critical Care, Sleep and Allergy Medicine, University of Nebraska Medical Center, Omaha, Nebraska, United States of America.
Amy J NelsonPulmonary, Critical Care, Sleep and Allergy Medicine, University of Nebraska Medical Center, Omaha, Nebraska, United States of America.
Jannah ObaidPulmonary, Critical Care, Sleep and Allergy Medicine, University of Nebraska Medical Center, Omaha, Nebraska, United States of America.
Alvaro Giron-MartinezPulmonary, Critical Care, Sleep and Allergy Medicine, University of Nebraska Medical Center, Omaha, Nebraska, United States of America.
Kumiko IkariPulmonary, Critical Care, Sleep and Allergy Medicine, University of Nebraska Medical Center, Omaha, Nebraska, United States of America.
Fumihiko MakinoPulmonary, Critical Care, Sleep and Allergy Medicine, University of Nebraska Medical Center, Omaha, Nebraska, United States of America.
Shunichiro IwasawaPulmonary, Critical Care, Sleep and Allergy Medicine, University of Nebraska Medical Center, Omaha, Nebraska, United States of America.
Yoko GunjiPulmonary, Critical Care, Sleep and Allergy Medicine, University of Nebraska Medical Center, Omaha, Nebraska, United States of America.
Maha FaridPulmonary, Critical Care, Sleep and Allergy Medicine, University of Nebraska Medical Center, Omaha, Nebraska, United States of America.
Xingqi WangPulmonary, Critical Care, Sleep and Allergy Medicine, University of Nebraska Medical Center, Omaha, Nebraska, United States of America.
Hesham BasmaPulmonary, Critical Care, Sleep and Allergy Medicine, University of Nebraska Medical Center, Omaha, Nebraska, United States of America.
Dawn DemeoChanning Laboratory, Harvard Medical School, Boston, Massachusetts, United States of America.
Carol Feghali-BostwickDivision of Rheumatology & Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, United States of America.
Olaf HolzFraunhofer ITEM, Member of the German Center for Lung Research (DZL, BREATH), Hannover, Germany.
Klaus RabeAirway Research Center North (ARCN), Lungen Clinic Grosshansdorf, Member of the German Center for Lung Research, Grosshansdorf, Germany.
Xiangde LiuPulmonary, Critical Care, Sleep and Allergy Medicine, University of Nebraska Medical Center, Omaha, Nebraska, United States of America.
Stephen I RennardPulmonary, Critical Care, Sleep and Allergy Medicine, University of Nebraska Medical Center, Omaha, Nebraska, United States of America.ORCID http://orcid.org/0000-0001-7909-0253
University of Nebraska Medical Center · USChiba University · JPFraunhofer Institute for Toxicology and Experimental Medicine · DEGerman Center for Lung Research · DEHarvard University · USMedical University of South Carolina · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alterations in microRNA (miRNA) expression may contribute to COPD pathogenesis. In COPD, lung fibroblast repair functions are altered in multiple ways, including extracellular mediator release. Our prior study revealed miR-503 expression is decreased in COPD lung fibroblasts, although the exact role played by miR-503 is undetermined. The current study examined a role of miR-503 in cytokine, growth factor and fibronectin production by lung fibroblasts from patients with and without COPD. Primary adult lung fibroblasts were isolated from patients with or without COPD. MiR-503 expression and interleukin (IL)-6, -8, PGE2, HGF, KGF, VEGF and fibronectin release were examined with or without inflammatory cytokines, IL-1β and tumor necrosis factor (TNF)-α. MiR-503 expression was decreased in COPD lung fibroblasts. The expression of miR-503 was positively correlated with %FVC, %FEV1, and %DLco as well as IL-6, -8, PGE2, HGF, KGF, and VEGF in the absence or presence of IL-1ß/TNF-α. In addition, IL-8 and VEGF release from COPD lung fibroblasts were increased compared to those from control. Exogenous miR-503 inhibited VEGF release from primary adult and fetal lung fibroblasts but not IL-8 release. As expected, COPD fibroblasts proliferated more slowly than control fibroblasts. MiR-503 did not affect proliferation of either control or COPD lung fibroblasts. MiR-503 inhibition of VEGF protein production and mRNA was mediated by direct binding to the 3' untranslated region of VEGF mRNA. Endogenous miR-503 was differently regulated by exogenous stimulants associated with COPD pathogenesis, including IL-1ß/TNF-α, TGF-ß1 and PGE2. Endogenous miR-503 inhibition augmented VEGF release by IL-1ß/TNF-α and TGF-ß1 but not by PGE2, demonstrating selectivity of miR-503 regulation of VEGF. In conclusions, reduced miR-503 augments VEGF release from lung fibroblasts from patients with COPD. Since VEGF contributes to disturbed vasculature in COPD, altered miR-503 production might play a role in modulating fibroblast-mediated vascular homeostasis in COPD.

Indexed as

Gene Expression Regulation3' Untranslated RegionsAdultBase SequenceCase-Control StudiesCells, CulturedChronic DiseaseDinoprostoneExtracellular MatrixFemaleFibroblastsFibronectinsHumansInterleukin-1betaInterleukin-8Lung3' Untranslated RegionsDinoprostoneFibronectinsInterleukin-1betaInterleukin-8MicroRNAsMIRN503 microRNA, humanRNA, MessengerTumor Necrosis Factor-alphaVascular Endothelial Growth Factor A

Identifiers

PMID28880936
PMCPMC5589164
OpenAlexW2751152665

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.